Bausch Health Companies (BHC) Total Non-Current Liabilities (2009 - 2026)
Bausch Health Companies (BHC) posted Total Non-Current Liabilities of $24.9 billion for Q2 2026, little changed sequentially from $24.8 billion in Q1 2026, and down 5.25% YoY from $26.2 billion in Q2 2025.
Bausch Health Companies (BHC) Total Non-Current Liabilities (2009 - 2026) Analysis & Trends
Bausch Health Companies has reported Total Non-Current Liabilities for 18 years, with the latest figure at $24.9 billion in Q2 2026.
- Quarterly Total Non-Current Liabilities fell 5.25% year-over-year to $24.9 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $24.9 billion (down 5.25% YoY) and the FY2025 annual result came in at $25.2 billion, down 3.58% from the prior year.
- Total Non-Current Liabilities held at $24.9 billion in Q2 2026 per BHC's latest filing, from $24.8 billion in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $28.7 billion in Q1 2022 and troughed at $24.5 billion in Q2 2023.
- A 5-year average of $25.9 billion and a median of $25.9 billion in 2024 frame the typical range for Total Non-Current Liabilities.
- The widest YoY moves for Total Non-Current Liabilities: up 7.98% in 2023, down 14.41% in 2023.
- Over 5 years, Total Non-Current Liabilities stood at $24.7 billion in 2022, then advanced by 7.98% to $26.7 billion in 2023, then declined by 1.97% to $26.1 billion in 2024, then fell by 3.58% to $25.2 billion in 2025, then slipped by 1.32% to $24.9 billion in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $24.9 billion, $24.8 billion, and $25.2 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | -13.28 Bn |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 16.45 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 33.50 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 18.76 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 1.37 Bn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 6.42 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 334.00 Mn |
| 10 | Bausch Health Companies | 2.42 Bn | 586.38 Mn | 2.10 Bn | 24.86 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 24.86 Bn |
| Mar 31, 2026 | 24.82 Bn |
| Dec 31, 2025 | 25.20 Bn |
| Sep 30, 2025 | 25.63 Bn |
| Jun 30, 2025 | 26.24 Bn |
| Mar 31, 2025 | 25.90 Bn |
| Dec 31, 2024 | 26.13 Bn |
| Sep 30, 2024 | 25.98 Bn |
| Jun 30, 2024 | 25.98 Bn |
| Mar 31, 2024 | 26.34 Bn |
| Dec 31, 2023 | 26.66 Bn |
| Sep 30, 2023 | 26.58 Bn |
| Jun 30, 2023 | 24.49 Bn |
| Mar 31, 2023 | 24.55 Bn |
| Dec 31, 2022 | 24.69 Bn |
| Sep 30, 2022 | 25.25 Bn |
| Jun 30, 2022 | 27.39 Bn |
| Mar 31, 2022 | 28.69 Bn |
| Dec 31, 2021 | 28.58 Bn |
| Sep 30, 2021 | 28.52 Bn |